Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Abiomed, Inc. (NASDAQ: ABMD), a leader in heart support technologies, announced that CEO Michael R. Minogue will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference. The virtual event is scheduled for February 17, 2022, at 10:40 AM. The company specializes in medical devices aimed at improving blood flow and heart function. Abiomed urges investors to consider potential risks reflected in forward-looking statements and to review their SEC filings for detailed information.

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11^th Annual Global Healthcare Conference (virtual) on Thursday, February 17, 2022 at 10:40am.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including with respect to Abiomed's development of existing and new products, the Company's commercial growth, future business opportunities and pending regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including uncertainties related to the scope, extent and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the possibility of future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological changes, governmental requirements, litigation, future capital requirements and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent filings with the SEC. Readers of this press release are advised not to evaluate forward-looking statements, which reflect information available only as of the date of this release, as reliable information. The Company is under no obligation to release updates to these forward-looking statements to reflect events or circumstances occurring after the date of the release or as a result of the impact of unforeseen events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005815/en/

Todd Trapp

Vice President and Chief Financial Officer

978-646-1680

ttrapp@abiomed.com

Source: Abiomed, Inc.

FAQ

When is Abiomed's CEO speaking at the SVB Leerink conference?

Michael R. Minogue will hold a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 10:40 AM.

What is the focus of Abiomed, Inc.?

Abiomed, Inc. focuses on providing breakthrough heart support technologies and medical devices that improve blood flow and heart function.

What stock symbol represents Abiomed?

Abiomed is represented by the stock symbol ABMD on NASDAQ.

What should investors know about Abiomed's forward-looking statements?

Investors should be aware that forward-looking statements may not be reliable and are subject to various risks, including market uncertainties and regulatory approvals.

Where is Abiomed, Inc. headquartered?

Abiomed, Inc. is headquartered in Danvers, Massachusetts.